Atara Biotherapeutics, Inc.

NASDAQ:ATRA

Biotechnology

Healthcare
$6.77 +1.96%

+$0.19 today

Market cap
$68.98M
Beta
0.11
P/E (TTM)
-14.7
EPS (TTM)
-$0.67
52W Low $3.92High $19.15

Volume 0.02M

Average 1.40M

ATRA Interest Income

Income earned on cash, deposits, and investments held by the company.

Atara Biotherapeutics, Inc.NASDAQ: ATRA

Interest Income · Q1 FY2026 · quarter ended Mar 2026

Interest income declines year over year

Q1 FY2026 interest income of $54K fell 77.1% year over year, behind the -71.2% change in trailing-twelve-month interest income. Sequentially, it fell 46.0% from the prior quarter. Over 3 fiscal years it compounded at -39.3% a year.

Context

  • Interest income amounted to 0.6% of revenue in FY2025, down 1.1 pp from a year earlier.
  • Interest income increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -77.1% toward the trailing-twelve-month pace of -71.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$54K-46.0% QoQ
Last fiscal yearDec 2025
$683K-67.6% YoY
LTMMar 2026
$501K-71.2% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-77.1%——
1 year-67.6%——
3-year CAGR-39.3%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
683K USD
Year-over-year change
-67.6%
4-year CAGR
+16.8%

Interest Income vs competitors

How ATRA compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -71.2% is the 6th highest of 8, against a peer median of -41.9%.
  • Interest income amounts to 2.2% of revenue for ATRA, versus a peer median of 5.8%.
ATRA Competitors
Interest Income for ATRA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$16.15M USD+417.4%-12.8%—
STROSutro Biopharma, Inc.LTM Mar 2026$7.7M USD-80.3%+38.9%7.7%
MGNXMacroGenics, Inc.LTM Mar 2026$5.93M USD-29.4%+26.0%3.8%
CNTXContext Therapeutics Inc.LTM Mar 2026$2.94M USD-26.6%+83.4%—
IFRXInflaRx N.V.LTM Mar 2026€1.62M EUR-41.9%+42.8%5520.1%
STTKShattuck Labs, Inc.LTM Mar 2026$779K USD-84.9%+19.3%77.9%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026$501K USD-71.2%-39.3%2.2%
CLNNClene Inc.LTM Mar 2026$189K USD-67.8%—141.0%
OVIDOvid Therapeutics Inc.LTM Mar 2026$0 USD——0.0%
COYACoya Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
CSBRChampions Oncology, Inc.LTM Jan 2026$0 USD——0.0%
Peer median (excluding ATRA) —-41.9%+32.4%5.8%

Competitors are the stored peer set for ATRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue20.34M63.57M8.57M128.94M120.77M
Cost of Revenue282M269.99M8.89M21.01M21.21M
Gross Profit(261.66M)(206.42M)(313K)107.93M99.56M
Gross Margin-1286.4%-324.7%-3.7%83.7%82.4%
Research & Development282M272.53M224.79M151.48M37.45M
Selling, General & Admin78.8M68.13M50.91M39.89M26.25M
Operating Expenses78.8M74.1M275.69M191.37M63.7M
Depreciation & Amortization9.35M5.65M4.83M5.05M2.12M
EBITDA(330.75M)(222.26M)(266M)(75.75M)38.63M
EBITDA Margin-1626.1%-349.6%-3102.7%-58.7%32.0%
Operating Income(340.46M)(280.51M)(276.01M)(83.44M)35.86M
Operating Margin-1673.9%-441.2%-3219.5%-64.7%29.7%
Interest Income367K3.06M5.43M2.11M683K
Interest Expense0373K5.29M4.62M3.79M
Other Income / Expenses367K52.22M(105K)(1.98M)(3.14M)
Income Before Tax(340.1M)(228.29M)(276.11M)(85.42M)32.72M
Pre-Tax Margin-1672.1%-359.1%-3220.7%-66.2%27.1%
Income Tax Expense46K12K15K(12K)31K
Net Income(340.14M)(228.3M)(276.13M)(85.4M)32.69M
Net Margin-1672.3%-359.1%-3220.9%-66.2%27.1%
EPS (Basic)(90.78)(55.96)(65.18)(11.41)2.61
EPS (Diluted)(90.78)(55.96)(65.18)(11.41)2.57
Weighted Avg Shares3.75M4.08M4.24M7.49M12.54M
Weighted Avg Shares (Diluted)3.75M4.08M4.24M7.49M12.72M

Atara Biotherapeutics, Inc.

NASDAQ:ATRA

Intrinsic Alpha fair value

Locked

Current Price

$6.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.